Prognostic analysis of liver transplantation in treating patients with end-stage autoimmune liver disease

Zou You; Zhang Lei; Li Ruidong; Guo Wenyuan; Ding Guoshan; Fu Zhiren; Wang Zhengxin

doi:10.3969/j.issn.1674-7445.2014.04.006

Volume 5 Issue 4

Jul. 2014

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2014 > 5(4): 222-226

Zou You, Zhang Lei, Li Ruidong, et al. Prognostic analysis of liver transplantation in treating patients with end-stage autoimmune liver disease[J]. ORGAN TRANSPLANTATION, 2014, 5(4): 222-226. doi: 10.3969/j.issn.1674-7445.2014.04.006

Citation:

PDF( 229 KB)

Prognostic analysis of liver transplantation in treating patients with end-stage autoimmune liver disease

doi: 10.3969/j.issn.1674-7445.2014.04.006

Organ Transplantation Center, Affiliated Changzheng Hospital, the Second Military Medical University, Shanghai 200003, China

Received Date: 2014-03-26
Available Online: 2021-01-19
Publish Date: 2014-07-15

Abstract

Abstract

Objective To investigate the prognosis of patients underwent liver transplantation (LT) for end-stage autoimmune liver disease (AILD). Methods Clinical data of 48 patients with end-stage AILD undergoing LT from May 1996 to April 2013 in Affiliated Changzheng Hospital of the Second Military Medical University were analyzed retrospectively. The postoperative cumulative survival rates of the recipients were calculated, and the cause of death was analyzed. The postoperative rejections, new-onset viral hepatitis and AILD recurrence were analyzed. Results In 48 AILD recipients, 38 cases survived and the postoperative 5-year cumulative survival rate was 76%. Causes of death for the 10 dead cases were multiple organ failure, liver graft failure, sepsis, pulmonary infection, hemorrhage, hepatic artery embolization and renal failure. In 48 AILD recipients, 9 cases (19%) suffered acute rejection after operation, 3 cases suffered new-onset hepatitis B infection in 1-2 years after operation, 2 recipients suffered primary disease (primary biliary cirrhosis) recurrence 2 years after operation and all survived for a long term after positive treatments. Conclusions Most liver transplant recipients with end-stage AILD can obtain a long-term survival. Attentions should be paid on the immunosuppressive regimens in early period after LT, prevention of infection, rejection and postoperative new-onset viral hepatitis, timely diagnosis of primary disease recurrence.
- Liver transplantation,
- Autoimmune liver disease,
- Autoimmune hepatitis,
- Primary biliary cirrhosis,
- Primary sclerosing cholangitis,
- Adrenocortical hormone

FullText(HTML)

References(17)

References

[1]	汤雯,贾继东.2012年自身免疫性肝脏疾病基础和临床进展[J].肝脏, 2013,18(8):559-562. http://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201308017.htm Tang W, Jia JD. Basic and clinical progress of autoimmune liver diseases in 2012[J]. Chin Hepatol,2013,18(8):559-562. http://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201308017.htm
[2]	陈虹,王旭,范铁艳,等.肝移植后新发自身免疫性肝炎一例诊疗体会[J].中华器官移植杂志,2013,34(4):248-249. Chen H, Wang X, Fan TY, et al. Diagnosis and treatment experience of de novo autoimmune hepatitis after liver transplantation: a case report[J]. Chin Organ Transplant,2013,34(4):248-249.
[3]	Harada K, Hsu M, Ikeda H, et al. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis[J]. J Clin Gastroenterol,2013,47(2):174-181. doi: 10.1097/MCG.0b013e31827234e4
[4]	Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems[J]. Hum Pathol,2013,44(6):1107-1117. doi: 10.1016/j.humpath.2012.09.017
[5]	Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation[J]. J Hepatol,2014,60(1):210-223. doi: 10.1016/j.jhep.2013.09.020
[6]	Singal AK, Guturu P, Hmoud B, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease[J]. Transplantation, 2013,95(5):755-760. doi: 10.1097/TP.0b013e31827afb3a
[7]	Goldberg DS, Camp A, Martinez-Camacho A, et al. Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis[J]. Liver Transpl,2013,19(3):250-258. doi: 10.1002/lt.v19.3
[8]	Kazma I, Lemoine R, Herr F, et al. Mycophenolic acid-treated dendritic cells generate regulatory CD4⁺ T cells that suppress CD8⁺ T cells' allocytotoxicity[J]. Int Immunol,2014,26(3):173-181. doi: 10.1093/intimm/dxt054
[9]	Jin X, Wang Y, Hawthorne WJ, et al. Enhanced suppression of the xenogeneic T-cell response in vitro by xenoantigen stimulated and expanded regulatory T cells[J]. Transplantation,2014,97(1):30-38. doi: 10.1097/TP.0b013e3182a860fa
[10]	Koga T, Ichinose K, Mizui M, et al. Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus[J]. J Immunol,2012,189(7):3490-3496. doi: 10.4049/jimmunol.1201785
[11]	Stallone G, Pontrelli P, Infante B, et al. Rapamycin induces ILT3(high) ILT4(high) dendritic cells promoting a new immunoregulatory pathway[J]. Kidney Int, 2014,85(4):888-897. doi: 10.1038/ki.2013.337
[12]	李敏如,汪根树,汪国营,等.肝移植术后合并脓毒症患者外周血调节性T细胞比例及功能变化的分析[J].器官移植,2013,4(3):145-150,164. http://www.organtranspl.com/browse/detail/qkid/64/id/280.html Li MR, Wang GS, Wang GY, et al. Analysis on percentage and function changes of peripheral regulatory T cell in patients with sepsis after liver transplantation[J]. Organ Transplant,2013,4(3):145-150,164. http://www.organtranspl.com/browse/detail/qkid/64/id/280.html
[13]	Lee CF, Eldeen FZ, Chan KM, et al. Bortezomib is effective to treat acute humoral rejection after liver transplantation[J]. Transplant Proc,2012,44(2):529-531. doi: 10.1016/j.transproceed.2012.01.051
[14]	Koch M, Gräser C, Lehnhardt A, et al. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib[J]. Transpl Int,2013,26(8):e64-e68. doi: 10.1111/tri.2013.26.issue-8
[15]	Sadaka B, Alloway RR, Woodle ES. Management of antibody-mediated rejection in transplantation[J]. Surg Clin North Am,2013,93(6):1451-1466. doi: 10.1016/j.suc.2013.08.002
[16]	Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review.[J] Liver Transpl,2006,12(12):1813-1824. doi: 10.1002/(ISSN)1527-6473
[17]	Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation[J]. Liver Transpl,2009,15(Suppl 2):S25-S34. doi: 10.1002/lt.v15.2s

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (95) PDF downloads(4)

Prognostic analysis of liver transplantation in treating patients with end-stage autoimmune liver disease

doi: 10.3969/j.issn.1674-7445.2014.04.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Prognostic analysis of liver transplantation in treating patients with end-stage autoimmune liver disease

doi: 10.3969/j.issn.1674-7445.2014.04.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content